Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 2;23(4):26.
doi: 10.1007/s11886-021-01455-w.

Mechanisms and Treatment of Dyslipidemia in Diabetes

Ehete Bahiru  1 , Ruth Hsiao  1 , Daniel Phillipson  1 , Karol E Watson  2
Affiliations
Review

Mechanisms and Treatment of Dyslipidemia in Diabetes

Ehete Bahiru et al. Curr Cardiol Rep. .

Abstract

Purpose of review: Type 2 diabetes mellitus is widespread throughout the world and is a powerful risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). This manuscript explored the mechanisms underlying dyslipidemia in type 2 diabetes as well as currently available treatment options and guideline recommendations.

Recent findings: Type 2 diabetes is associated with a characteristic pattern of dyslipidemia, often termed diabetic dyslipidemia. Patients with type 2 diabetes often present with low HDL levels, elevated levels of small dense LDL particles, and elevated triglyceride levels. LDL lowering is the cornerstone of managing diabetic dyslipidemia, and statins are the mainstay of therapy. The cholesterol absorption inhibitor ezetimibe and PCSK9 inhibitors have also been shown to lower risk in patients with diabetes. Recently, the eicosapentaenoic (EPA) only n-3 fatty acid, icosapent ethyl, has also shown benefit for cardiovascular risk reduction in patients with diabetes. To date, no agents targeting HDL increase have shown cardiovascular benefit in patients on background statin therapy. Diabetic dyslipidemia is significant cardiovascular disease risk factor, and LDL-lowering therapy with statins, PCSK9 inhibitors, and ezetimibe continues to be mainstay therapy to reduce cardiovascular risk. Future studies targeting low HDL and high triglycerides levels associated with type 2 diabetes could provide additional novel therapies to manage diabetic dyslipidemia.

Keywords: Atherosclerotic cardiovascular disease; Dyslipidemia; Type 2 diabetes.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Virani SS. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596. https://doi.org/10.1161/CIR.0000000000000757 . - DOI - PubMed
    1. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 23(2):201–29. https://doi.org/10.1210/edrv.23.2.0461 .
    1. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57(4):551–60. https://doi.org/10.1016/0002-9343(74)90006-0 . - DOI - PubMed
    1. Lewis GF, Uffelman KD, Szeto, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes. 1993;42:833–942. https://doi.org/10.2337/diab.42.6.833 . - DOI - PubMed
    1. Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract. 2002;56(3):181–7. https://doi.org/10.1016/s0168-8227(01)00369-2 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources